CA2023630A1 - Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs - Google Patents

Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs

Info

Publication number
CA2023630A1
CA2023630A1 CA002023630A CA2023630A CA2023630A1 CA 2023630 A1 CA2023630 A1 CA 2023630A1 CA 002023630 A CA002023630 A CA 002023630A CA 2023630 A CA2023630 A CA 2023630A CA 2023630 A1 CA2023630 A1 CA 2023630A1
Authority
CA
Canada
Prior art keywords
toremifene
reversal
cancer cells
multidrug resistance
metabolites
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002023630A
Other languages
French (fr)
Other versions
CA2023630C (en
Inventor
Adrian Llewellyn Harris
Lauri Veikko Matti Kangas
Michael William Degregorio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Yale University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2023630A1 publication Critical patent/CA2023630A1/en
Application granted granted Critical
Publication of CA2023630C publication Critical patent/CA2023630C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A compound comprising toremifene or its metabolite N-demethyltoremifene or 4-hydroxytoremifene, or a non-toxic pharmaceutically acceptable salt thereof may be used for the reversal of multidrug resistance of cancer cells to cytotoxic drugs in the treatment of cancer with at least one cytotoxic drug.
CA002023630A 1989-08-23 1990-08-20 Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs Expired - Lifetime CA2023630C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/397,551 US4990538A (en) 1989-08-23 1989-08-23 Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
US397,551 1989-08-23

Publications (2)

Publication Number Publication Date
CA2023630A1 true CA2023630A1 (en) 1991-02-24
CA2023630C CA2023630C (en) 2002-02-19

Family

ID=23571649

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002023630A Expired - Lifetime CA2023630C (en) 1989-08-23 1990-08-20 Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs

Country Status (11)

Country Link
US (1) US4990538A (en)
EP (1) EP0415623A3 (en)
JP (1) JP3186759B2 (en)
KR (1) KR0171893B1 (en)
AU (1) AU633954B2 (en)
CA (1) CA2023630C (en)
HU (1) HU215913B (en)
IE (1) IE67639B1 (en)
NZ (1) NZ234999A (en)
PH (1) PH27064A (en)
ZA (1) ZA906670B (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5491173A (en) * 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
US5114951A (en) * 1989-04-11 1992-05-19 Burroughs Wellcome Company Agents for combating multiple drug resistance
US5162581A (en) * 1989-05-29 1992-11-10 Takaru Shuzo Co., Ltd. Crystalline deoxyspergualin, process for its preparation and suppository containing the same
GB8914060D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914062D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
GB8914040D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5114919A (en) * 1990-02-26 1992-05-19 Merck & Co., Inc. Adjuncts in cancer chemotherapy
ITRM910192A1 (en) * 1990-04-03 1991-10-04 American Cyanamid Co METHOD FOR INVERTING THE RESISTANCE TO BISANTRENE MEDIATED BY P-GLYCOPROTEINS.
US6515009B1 (en) * 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
ATE142879T1 (en) * 1992-02-06 1996-10-15 Merrell Pharma Inc RESOLUTION OF MULTI-DRUG RESISTANCE BY TETRAARYLETHYLENE
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) * 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5840319A (en) * 1992-10-08 1998-11-24 Alakhov; Valery Yu Biological agent compositions
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US5886049A (en) 1992-10-27 1999-03-23 Nippon Kayaku Kabushiki Kaisha Remedy for autoimmune diseases
WO1994009764A1 (en) * 1992-10-27 1994-05-11 Nippon Kayaku Kabushiki Kaisha Use of non steroidal anti estrogens for autoimmune diseases
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
JPH08510451A (en) * 1993-05-13 1996-11-05 ネオルックス コーポレイション Prevention and treatment of pathogenesis associated with hyperproliferative smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
US5432168A (en) * 1993-12-27 1995-07-11 University Of Manitoba Method of treatment of hormone-unresponsive metastatic prostate cancer
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
US5571687A (en) * 1994-06-07 1996-11-05 Duke University Modulators of multidrug resistance transporters
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US5767113A (en) * 1995-05-10 1998-06-16 The Salk Institute For Biological Studies Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
US5852033A (en) * 1995-06-29 1998-12-22 Pharma Mar, S.A. Methods of treatment using lamellarin-class alkaloids
AU6959898A (en) 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6413534B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
HRP20000729A2 (en) * 1998-05-07 2001-06-30 Univ Tennessee Res Corp A method for chemoprevention of prostate cancer
US20040176470A1 (en) * 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6632447B1 (en) 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
KR20010080254A (en) * 1998-11-26 2001-08-22 야마구찌 다까시 Medicinal compositions for periodic administration
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
US10201589B2 (en) 2013-12-11 2019-02-12 University Of Massachusetts Compositions and methods for treating disease using Salmonella T3SS effector protein (SipA)
WO2016106146A1 (en) 2014-12-23 2016-06-30 The Regents Of The University Of California Methods for immunomodulation of cancer and infectious disease therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0680016B2 (en) * 1984-08-02 1994-10-12 ラブリ−，フエルナンド Pharmaceutical composition for combined treatment of hormone-dependent cancer

Also Published As

Publication number Publication date
KR0171893B1 (en) 1999-02-01
ZA906670B (en) 1991-06-26
IE67639B1 (en) 1996-04-17
PH27064A (en) 1993-02-01
US4990538A (en) 1991-02-05
JP3186759B2 (en) 2001-07-11
HU905276D0 (en) 1991-02-28
KR910004185A (en) 1991-03-28
NZ234999A (en) 1997-06-24
AU6113390A (en) 1991-02-28
AU633954B2 (en) 1993-02-11
JPH03163015A (en) 1991-07-15
EP0415623A3 (en) 1991-04-03
HUT58511A (en) 1992-03-30
HU215913B (en) 1999-03-29
IE903044A1 (en) 1991-02-27
EP0415623A2 (en) 1991-03-06
CA2023630C (en) 2002-02-19

Similar Documents

Publication Publication Date Title
CA2023630A1 (en) Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
CA2239174A1 (en) Novel compounds with analgesic effect
CA2133429A1 (en) Topical administration of toremifene and its metabolites
ES2001996A6 (en) Medicament against chronic graft-versus-host diseases, as well as against autoimmune diseases, particularly systemic lupus erythematodes.
AU569431B2 (en) Pharmaceutical composition containing phenindamine
EP0663401A4 (en) Morphinan derivative and medicinal use.
IT8619004A0 (en) WATER-SUBLY SALTS OF COMPOUNDS WITH ANTI-INFLAMMATORY AND ANALGESIC ADAPTIVITY, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS.
IE843166L (en) Pharmaceutical composition - xanthine derivatives
HUT55220A (en) Process for producing pharmaceutical composition suitable for systemic administration through the skin and comprising deprenyl as active ingredient
ATA195588A (en) EPIPODOPHYLLOTOXINGLUCOSIDE-4'-PHOSPHATE DERIVATIVES THE PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITIONS THEREOF
CA2021574A1 (en) Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
IT1134638B (en) IMPROVEMENTS CARRIED OUT IN THE PROCEDURES FOR THE PREPARATION OF GALENIC FORMS WITH DELAYED ACTION AND FOR PROGRAMMED LIBERATION, AND GALENIC FORMS OF MEDICAMENTS THUS OBTAINED
IT1219811B (en) PEPTIDAL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICATIONS
IT1226549B (en) PHARMACEUTICAL COMPOSITIONS WITH ANALGESIC AND ANTI-INFLAMMATORY ACTIVITY FOR ORAL USE, EQUIPPED WITH EXCELLENT PALATABILITY AND FREE FROM IRRITATING EFFECTS ON MUCOSES.
CA2093666A1 (en) Orally administered solvent-free pharmaceutical preparation with delayed active-substance release, and a method of preparing the preparation
IT1148277B (en) ENCEPHALINIC DERIVATIVES EQUIPPED WITH ANALGESIC AND QUIET NEUROLEPTIC ACTIVITY AND PROCEDURE FOR THEIR PREPARATION
CA2251966A1 (en) Transdermally administered dextromethorphan as antitussive agent
HK80492A (en) Pharmaceutical compositions with analgesic properties and the preparation and use thereof
AU4345489A (en) Anti-inflammatory and analgesic compounds, related compositions and methods for preparation and use thereof
AU7885991A (en) 1,4-dihydropyridines for application in combatting resistance to drugs
ZA894422B (en) Pyrrole derivatives,their preparation and their use as pharmaceutical active compounds
IT1200931B (en) TRIAZINIC DERIVATIVES EQUIPPED WITH ANALGESIC, ANTI-PIRETIC AND ANTI-INFLAMMATORY ACTIVITIES
FR2572932B1 (en) INSOLUBLE DRUG LOCALLY ADMINISTERED IN THE EAR
CA2077762A1 (en) New use of bambuterol
EP0345883A3 (en) Use of dapiprazole for the manufacture of a pharmaceutical composition inhibiting the development of tolerance in the analgesic treatment with morphine

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKEC Expiry (correction)
MKEC Expiry (correction)

Effective date: 20121202